But a previous study has indicated that only 44.8% of NSCLC patients achieved an objective response when treated with PD-L1 antibody pembrolizumab monotherapy, even in a highly selected patient population (PD-L1 expression ≥50%) [8]. Here, CD274 is linked to non-small cell lung carcinoma.